Buy & Sell BIO-TECHNE Corp (TECH) – BIO-TECHNE Corp Price Today
Aura AI Summary
Key Stats
- $7.55BMarket Cap
- HealthSector
- -28.51%3M Drawdown
- $7.63BEnterprise Value
- 0.66%Dividend Yield
- 63 daysTypical Hold Time
BIO-TECHNE Corp (TECH) is currently valued at a market capitalization of $7.55B, with an enterprise value of $7.63B. Over the past 52 weeks, BIO-TECHNE Corp has traded between a low of $43.31 and a high of $71.38, highlighting its annual price range. Over the past three months, BIO-TECHNE Corp has recorded a drawdown of -28.51%, reflecting recent price volatility. BIO-TECHNE Corp offers a dividend yield of 0.66%, with the most recent dividend of $0.08 paid on 18 May 26. On average, investors hold BIO-TECHNE Corp for approximately 63 days, indicating typical investor behavior on the platform.
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Most Recent News
Investigation launched over Regeneron’s optimistic trial claims that preceded stock drop.
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a ...
Investigation launched into Prestige Consumer Healthcare over missed earnings and undisclosed acquisition
Levi & Korsinsky has started an investigation into Prestige Consumer Healthcare following the company's failure to meet its Q4 and full-year financial projections, including adjusted gross margin, free cash flow, and adjusted EPS. Additionally, Prest...
Investigation launched into TriSalus Life Sciences after Q1 revenue misses estimates and cuts full-year guidance
Levi & Korsinsky has started an investigation into TriSalus Life Sciences following the company's Q1 2026 revenue of $8.9 million, which missed Wall Street's $9.4 million estimate. The company also lowered its full-year 2026 revenue forecast to $54 m...